Viewmind

ViewMind for pharmaceutical companies

Higher clinical trial screening accuracy. Quantified drug impact.

Clinical studies for CNS drugs have a much lower success rate for FDA approval than non-CNS drugs (6.2% vs 13.3%). Patient recruitment can also be challenging and costly. For Alzheimer’s drug studies, the screen failure rate in at-risk populations is typically 70-75%. ViewMind technology can help you speed up your screening, reduce its costs, ensure cohorts are cognitively matched, and measure the impact of new drugs.

Pre-screen a prospective study participant in 15 minutes

ViewMind can reduce screen failure rates by more than 50% with a non-invasive, 15-minute pre-screening for better cohort harmonization and stratification that will boost the statistical significance of the results.

Quantifying the impact of new drugs on cognitive health

ViewMind can give you access to critical, frequently updated, individualized data to complement pathological biomarker results, so that you can achieve better patient outcomes.

Group 10754

Ojaswi Rana
Best Practices Research Analyst - Frost & Sullivan

“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology. 


The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment.”

image 4 (1)

Using ViewMind in clinical trials

Group 10634

Increase the likelihood of successful clinical trials

Assess brain health by cognitive domain through a non-invasive, scalable and accurate pre-screening.

 

Identify patients for treatment and frequently measure treatment progress throughout your clinical trial with an objective, scalable solution.

 

Improve patient cohort harmonization, stratification and the statistical significance of clinical studies.

Group 10632 (1)

Measure therapeutic impact 

Measure the impact of a drug or a digital therapeutic on different cognitive domains of clinical trial participants.

 

ViewMind works in people independent of age, educational levels, and cultural background.

 

Run inclusive studies that address diverse communities and healthcare disparities.

Group 10633 (1)

Improve clinical outcomes

Measure individual patient response to treatment and monitor progress in short time intervals.

 

Use a scalable, non-invasive test combined with precision cognition measurement.

 

Identify early subclinical disease and its progression. 

Increase the likelihood of successful clinical trials

Assess brain health by cognitive domain as a non-invasive, scalable and accurate pre-screening.

Measure treatment progress throughout your clinical trial with an affordable solution.

Improve patient cohort harmonization, stratification, reduce selection bias and increase the statistical significance of clinical studies.

Measure therapeutic impact

Measure the impact of a drug or a digital therapeutic on different cognitive domains of clinical trial participants.

ViewMind works for participants independent of age, educational levels, and cultural background.

Now you can facilitate inclusive studies that address diverse communities and healthcare disparities.

Improve clinical outcomes

Measure individual patient response to treatment and monitor progress in short time intervals.

A scalable, non-invasive test combined with precision cognition measurement.

Detect early subclinical disease and progression with much of the value of a PET, CSF and MRI but non-invasive and affordable.
Mark email read

Reach out to
collaborate on a clinical
trial. Click to follow
ViewMind on LinkedIn
and Twitter

Group 10694
Group 10695

For collaboration on clinical trials please complete the form